Traduction de «annual report and other » (Néerlandais → Français) :

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

As also discussed in notes 9 and 10 of the 2008 Annual Report, other intangible assets and investments in associated companies are reviewed for impairment whenever an event or decision occurs that raises concern about their balance sheet carrying value.
Comme le notent également les annexes 9 et 10 du Rapport annuel 2008, les autres immobilisations incorporelles et investissements dans des sociétés associées font l’objet d’un test de dépréciation dès lors qu’un événement ou une décision les concernant suscitent des doutes quant à leur valeur inscrite au bilan.

The following is a non-exhaustive list relating to some cases reported in the 2009 Annual Report and other cases of significance, and includes information as of October 21, 2010:
La liste suivante, non exhaustive, passe en revue quelques-uns des cas cités dans le Rapport annuel 2009 ainsi que d’autres cas importants et contient les informations disponibles au 21 octobre 2010.

The following is a non-exhaustive list relating to some cases reported in the 2009 Annual Report and other cases of significance, and includes information as of July 15, 2010:
La liste suivante, non exhaustive, passe en revue quelques-uns des cas cités dans le Rapport annuel 2009 ainsi que d’autres cas importants et contient les informations disponibles au 15 juillet 2010.

Startpagina » Publications » Other series » Annual reports
Accueil » Publications » Other series » Annual reports

See note 20 in the Group’s Consolidated Financial Statements in the 2009 Annual Report for a summary of major legal proceedings. The following is a non-exhaustive list relating to some cases reported in the 2009 Annual Report and includes information as of the 2009 fourth quarter:
Pour un résumé des litiges majeurs, prière de consulter la note 20 des Comptes consolidés du Groupe figurant dans le rapport annuel 2009.La liste suivante, non exhaustive, passe en revue quelquesuns des cas cités dans le Rapport annuel 2009 et contient les informations disponibles au quatrième trimestre 2009.

These Condensed Interim Consolidated Financial Statements for the three- and sixmonth periods ended June 30, 2009, were prepared in accordance with International Accounting Standard 34 Interim Financial Reporting and accounting policies set out in the 2008 Annual Report published on January 28, 2009.
Les comptes intermédiaires consolidés simplifiés pour les périodes de trois et six mois se terminant le 30 juin 2009 ont été établis conformément à la norme comptable internationale 34 Information financière intermédiaire et aux normes comptables décrites dans le rapport annuel 2008 publié le 28 janvier 2009.

The following is a non-exhaustive list relating to some cases reported in the 2008 Annual Report and includes information as of the 2009 first half:
Non exhaustive, la liste suivante passe en revue quelques-uns des cas cités dans le Rapport annuel 2008 et contient les informations disponibles au premier semestre 2009.

The principal accounting policies of Novartis are set out in note 1 to the Consolidated Financial Statements in the 2008 Annual Report and conform with International Financial Reporting Standards (IFRS).
Les principales normes comptables appliquées par Novartis sont exposées dans l’annexe 1 aux comptes consolidés du Groupe figurant dans le Rapport annuel 2008 et satisfont aux normes International Financial Reporting Standards (IFRS).

A further list and description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2010 and in its reports on Form 10-Q and Form 8-K. # # # # #
A further list and description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2010 and in its reports on Form 10-Q and Form 8-K.